Clinical Trial Update: Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating icotinib in combination with SBRT for patients with metastatic non-squamous non-small cell lung cancer harboring EGFR mutation…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Sichuan Cancer Hospital and Research Institute | Conditions: Lung Cancer Stage IV | Phase 2 | Status: UNKNOWN